Sushrut Ingawale

Dr. Sushrut Ingawale

Internal Medicine, Quinnipiac University, Hamden, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2019 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MBMansij Biswas
Mansij Biswas
KSKritarth Naman Mithileshwar Singh
Kritarth Naman Mithileshwar Singh
YSYashashri C. Shetty
Yashashri C. Shetty
PKParesh G. Koli
Paresh G. Koli
SISushrut Ingawale
Sushrut Ingawale
SBShobna J. Bhatia
Shobna J. Bhatia
Background & objectives: Prokinetics are extensively prescribed leading to several adverse events (AEs). The aim of this study was to assess the prescription pattern in patients receiving prokinetics, and characteristics of adverse drug reactions (ADRs) in an outpatient department set up in a tertiary care hospital in western India. Methods: Patients attending outpatient departments of a tertiary care hospital and who had received prokinetic agent for at least seven days over the last one month were enrolled. Causality assessment of AEs was done and assessed for severity, preventability, seriousness and predictability. Results: A total of 304 patients [161 males (52.96%); 143 females (47.04%)] were enrolled. Most prescriptions (299/304, 98%) included domperidone, most commonly prescribed as fixed-dose combination (FDC) with pantoprazole (274/304, 90%). Prokinetic dose was not mentioned in 251/304 (83%) prescriptions, and 18/304 (6%) did not mention frequency. Of the 378 AEs reported from 179 patients (47.35%), 306 (81%) were mild, all non-serious; 272 (72%) not preventable and 291 (77%) predictable in nature. Decreased appetite (n=31, 8.2%) and fatigue (n=27,7.14%) were most commonly reported. Causality assessment by the World Health Organization-Uppsala Monitoring Centre scale showed that 180 AEs were related to suspected drug (17 probable and 163 possible ADRs). Significant correlation was observed for AEs with increasing number of drugs per prescription (Spearman's R=+0.8, P=0.05) and with increasing therapy duration (Spearman's R=+1.00, P<0.001). Interpretation & conclusions: Our findings showed that prokinetics were often prescribed as FDCs, with incomplete prescriptions. Domperidone was found to be associated with multiple AEs. It is suggested that regular prescription monitoring should be done in hospitals to encourage rational use of drugs.

2 June 2025 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
JUJahnavi Udaikumar
Jahnavi Udaikumar
RNRithish Nimmagadda
Rithish Nimmagadda
SISushrut Ingawale
Sushrut Ingawale
VLVindhya vasini Lella
Vindhya vasini Lella
KVKeerthika Vijayakumar
Keerthika Vijayakumar
ASAasma Shaukat
Aasma Shaukat

1 May 2022
Verified
Journal Article
Closed access
ARAnjali Rajadhyaksha
Anjali Rajadhyaksha
NSNitin Sarate
Nitin Sarate
NRNilesh Raghorte
Nilesh Raghorte
SISushrut Ingawale
Sushrut Ingawale

1 April 2021
Verified
Journal Article
Closed access
NSNeena Sawant
Neena Sawant
SISushrut Ingawale
Sushrut Ingawale
ULUrja Lokhande
Urja Lokhande
SPSanket Patil
Sanket Patil
EAEera Fatima Mohammed Ayub
Eera Fatima Mohammed Ayub
VRVedant Rathi
Vedant Rathi

15 April 2023 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SGSuprabhat Giri
Suprabhat Giri
ASAnkita Singh
Ankita Singh
JVJijo Varghese
Jijo Varghese
SISushrut Ingawale
Sushrut Ingawale
ARAkash Roy
Akash Roy
Background: Portal hypertension in cirrhosis brings about a complex interplay in the risks of bleeding and thrombosis. It is unclear whether hospitalized patients with cirrhosis need pharmacological prophylaxis for venous thromboembolism (VTE), as it may increase the risk of bleeding. We aimed to compare the outcome of hospitalized patients with cirrhosis with and without pharmacological thromboprophylaxis. Methods: A comprehensive search of three databases was conducted from inception to August 2022 for studies comparing the outcome of hospitalized patients with cirrhosis with and without pharmacological prophylaxis for VTE. Odds ratios (OR) with 95% confidence intervals (CIs) were calculated for the outcomes of VTE or bleeding. Results: Overall, 12 studies were included in the final analysis. The pooled incidence of VTE in patients with and without thromboprophylaxis was 1.9% (95% CI: 0.8–2.9) and 1.9% (95% CI: 0.9–2.9), respectively. The odds of VTE were comparable between the groups with OR 1.11 (95% CI: 0.76–1.62). The pooled incidence of bleeding events in patients with and without thromboprophylaxis was 6.7% (95% CI: 3.6–9.8) and 10.4% (95% CI: 6.6–14.1), respectively. There was no significant difference in the odds of overall bleeding (OR 0.68; 95% CI: 0.30–1.52) or major bleeding (OR 1.18; 95% CI: 0.55–2.56) between the groups. There was no significant difference in the relative effects on sensitivity analysis. Conclusion: The present analysis could not demonstrate the benefit of pharmacological thromboprophylaxis in reducing in-hospital VTE in patients with cirrhosis. Future studies are required to assess the role of risk prediction models in hospitalized patients with cirrhosis.